Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia

Optimal conditioning chemotherapy for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) remains uncertain. Myeloablative regimens such as fludarabine/busulfan are favored over reduced-intensity fludarabine/melphalan (Flu/Mel); however, it is not known if Flu/Mel is inferi...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Leuk Lymphoma
Auteurs principaux: DiMaggio, Elizabeth, Zhou, Jun-Min, Caddell, Ryan, Tombleson, Rebecca, Perkins, Janelle, Anasetti, Claudio, Khimani, Farhad, Pidala, Joseph, Nishihori, Taiga, Perez, Lia, Betts, Brian, Fernandez, Hugo F., Mishra, Asmita
Format: Artigo
Langue:Inglês
Publié: 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7771324/
https://ncbi.nlm.nih.gov/pubmed/32133897
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2020.1731498
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires